CR10505A - Aminopirazolopiridinas sustituidas y sus sales, sus preparaciones y composiciones farmaceuticas que las comprenden - Google Patents
Aminopirazolopiridinas sustituidas y sus sales, sus preparaciones y composiciones farmaceuticas que las comprendenInfo
- Publication number
- CR10505A CR10505A CR10505A CR10505A CR10505A CR 10505 A CR10505 A CR 10505A CR 10505 A CR10505 A CR 10505A CR 10505 A CR10505 A CR 10505A CR 10505 A CR10505 A CR 10505A
- Authority
- CR
- Costa Rica
- Prior art keywords
- aminopirazolopiridinas
- preparations
- salts
- understand
- replaced
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06090109A EP1867648A1 (en) | 2006-06-13 | 2006-06-13 | Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them. |
| EP07090020 | 2007-02-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR10505A true CR10505A (es) | 2009-03-20 |
Family
ID=38445661
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR10505A CR10505A (es) | 2006-06-13 | 2008-12-12 | Aminopirazolopiridinas sustituidas y sus sales, sus preparaciones y composiciones farmaceuticas que las comprenden |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7846928B2 (es) |
| EP (1) | EP2061790B1 (es) |
| JP (1) | JP5475442B2 (es) |
| KR (1) | KR20090018212A (es) |
| AR (1) | AR061346A1 (es) |
| AU (1) | AU2007260216A1 (es) |
| BR (1) | BRPI0711961A2 (es) |
| CA (1) | CA2654789C (es) |
| CL (1) | CL2007001711A1 (es) |
| CR (1) | CR10505A (es) |
| EA (1) | EA200802407A1 (es) |
| EC (1) | ECSP088963A (es) |
| ES (1) | ES2515117T3 (es) |
| GT (1) | GT200800285A (es) |
| IL (1) | IL195813A0 (es) |
| MX (1) | MX2008015955A (es) |
| NO (1) | NO20090171L (es) |
| PE (1) | PE20080205A1 (es) |
| TW (1) | TW200815438A (es) |
| UY (1) | UY30409A1 (es) |
| WO (1) | WO2007144204A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20061119A1 (es) * | 2005-01-19 | 2006-11-27 | Aventis Pharma Sa | PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie |
| US8173635B2 (en) * | 2007-11-02 | 2012-05-08 | Vertex Pharmaceuticals Incorporated | Kinase inhibitors |
| CN102083794A (zh) * | 2008-05-05 | 2011-06-01 | 安姆根有限公司 | 作为γ分泌酶调节剂的脲化合物 |
| AU2009262199B2 (en) | 2008-06-27 | 2012-08-09 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
| CA2744154A1 (en) | 2008-11-20 | 2010-05-27 | Genentech, Inc. | Pyrazolopyridine pi3k inhibitor compounds and methods of use |
| EP2789614B1 (en) | 2009-08-11 | 2017-04-26 | Bristol-Myers Squibb Company | Azaindazoles as Btk kinase modulators and use thereof |
| EP2516437B1 (en) | 2009-12-21 | 2014-01-29 | Novartis AG | Disubstituted heteroaryl-fused pyridines |
| CN104334556B (zh) * | 2012-03-26 | 2017-05-17 | 爱若优生物科技有限公司 | 新型1‑磷酸鞘氨醇受体拮抗剂 |
| WO2013188848A2 (en) * | 2012-06-15 | 2013-12-19 | The Regents Of The University Of California | Antiviral compounds and methods of use |
| US11059817B2 (en) | 2015-09-23 | 2021-07-13 | The Regents Of The University Of California | Potent antiviral pyrazolopyridine compounds |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| SG11202001684PA (en) | 2017-10-06 | 2020-03-30 | Forma Therapeutics Inc | Inhibiting ubiquitin specific peptidase 30 |
| KR102526964B1 (ko) | 2018-02-26 | 2023-04-28 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 복제 억제제로서의 치환된 피롤리진 화합물 |
| ES2988920T3 (es) | 2018-05-17 | 2024-11-22 | Forma Therapeutics Inc | Compuestos bicíclicos fusionados útiles como inhibidores de la peptidasa 30 específica de ubiquitina |
| PL3860989T3 (pl) | 2018-10-05 | 2023-07-10 | Forma Therapeutics, Inc. | Sprzężone piroliny, które działają jako inhibitory proteazy 30 swoistej dla ubikwityny (usp30) |
| TW202136238A (zh) * | 2020-01-06 | 2021-10-01 | 大陸商廣東東陽光藥業有限公司 | RORγt抑制劑及其製備方法和用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6670364B2 (en) * | 2001-01-31 | 2003-12-30 | Telik, Inc. | Antagonists of MCP-1 function and methods of use thereof |
| JP4810427B2 (ja) * | 2003-05-22 | 2011-11-09 | アボット・ラボラトリーズ | インダゾール、ベンズイソオキサゾールおよびベンズイソチアゾールキナーゼ阻害剤 |
| EP1697369A1 (en) * | 2003-12-22 | 2006-09-06 | SB Pharmco Puerto Rico Inc | Crf receptor antagonists and methods relating thereto |
| FR2876691B1 (fr) * | 2004-10-18 | 2006-12-29 | Sanofi Aventis Sa | Derives de pyridine, leur preparation, leur application en therapeutique |
| US7812166B2 (en) * | 2004-10-29 | 2010-10-12 | Abbott Laboratories | Kinase inhibitors |
| PE20061119A1 (es) * | 2005-01-19 | 2006-11-27 | Aventis Pharma Sa | PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie |
| EP1683796A1 (en) * | 2005-01-24 | 2006-07-26 | Schering Aktiengesellschaft | Pyrazolopyridines, their preparation and their medical use |
| WO2007000241A1 (en) * | 2005-06-27 | 2007-01-04 | Sanofi-Aventis | Pyrazolopyridine derivatives as inhibitors of beta-adrenergic receptor kinase 1 |
-
2007
- 2007-06-11 TW TW096121006A patent/TW200815438A/zh unknown
- 2007-06-12 UY UY30409A patent/UY30409A1/es not_active Application Discontinuation
- 2007-06-12 CL CL2007001711A patent/CL2007001711A1/es unknown
- 2007-06-12 ES ES07764753.5T patent/ES2515117T3/es active Active
- 2007-06-12 EP EP07764753.5A patent/EP2061790B1/en active Active
- 2007-06-12 AR ARP070102552A patent/AR061346A1/es unknown
- 2007-06-12 US US11/761,672 patent/US7846928B2/en not_active Expired - Fee Related
- 2007-06-12 WO PCT/EP2007/005432 patent/WO2007144204A1/en not_active Ceased
- 2007-06-12 PE PE2007000741A patent/PE20080205A1/es not_active Application Discontinuation
- 2007-06-12 KR KR1020097000562A patent/KR20090018212A/ko not_active Withdrawn
- 2007-06-12 EA EA200802407A patent/EA200802407A1/ru unknown
- 2007-06-12 MX MX2008015955A patent/MX2008015955A/es not_active Application Discontinuation
- 2007-06-12 JP JP2009514716A patent/JP5475442B2/ja not_active Expired - Fee Related
- 2007-06-12 CA CA2654789A patent/CA2654789C/en not_active Expired - Fee Related
- 2007-06-12 BR BRPI0711961-5A patent/BRPI0711961A2/pt not_active IP Right Cessation
- 2007-06-12 AU AU2007260216A patent/AU2007260216A1/en not_active Abandoned
-
2008
- 2008-12-09 IL IL195813A patent/IL195813A0/en unknown
- 2008-12-12 EC EC2008008963A patent/ECSP088963A/es unknown
- 2008-12-12 CR CR10505A patent/CR10505A/es not_active Application Discontinuation
- 2008-12-12 GT GT200800285A patent/GT200800285A/es unknown
-
2009
- 2009-01-12 NO NO20090171A patent/NO20090171L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2654789A1 (en) | 2007-12-21 |
| EP2061790B1 (en) | 2014-08-13 |
| MX2008015955A (es) | 2009-01-09 |
| ES2515117T3 (es) | 2014-10-29 |
| CA2654789C (en) | 2014-08-05 |
| GT200800285A (es) | 2009-03-09 |
| US7846928B2 (en) | 2010-12-07 |
| EP2061790A1 (en) | 2009-05-27 |
| JP2009539914A (ja) | 2009-11-19 |
| WO2007144204A1 (en) | 2007-12-21 |
| UY30409A1 (es) | 2008-01-31 |
| AU2007260216A1 (en) | 2007-12-21 |
| US20080058326A1 (en) | 2008-03-06 |
| CL2007001711A1 (es) | 2008-01-04 |
| BRPI0711961A2 (pt) | 2012-01-17 |
| PE20080205A1 (es) | 2008-06-01 |
| EA200802407A1 (ru) | 2009-06-30 |
| TW200815438A (en) | 2008-04-01 |
| ECSP088963A (es) | 2009-01-30 |
| NO20090171L (no) | 2009-03-12 |
| IL195813A0 (en) | 2009-09-22 |
| AR061346A1 (es) | 2008-08-20 |
| KR20090018212A (ko) | 2009-02-19 |
| JP5475442B2 (ja) | 2014-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTPA2018005I1 (lt) | Farmacinė kompozicija | |
| BRPI0807907A2 (pt) | co-cristais e composições farmacêuticas compreendendo os mesmos. | |
| BRPI0820381A2 (pt) | Formulações farmacêuticas | |
| UA14280S (uk) | Футляр для косметичного виробу | |
| NO20075628L (no) | Farmasøytiske formuleringer | |
| DK2068886T3 (da) | Lipidholdige præparater | |
| DK3421471T3 (da) | Purin- og deazapurinderivater som farmaceutiske forbindelser | |
| EP2124556A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| ITBO20050123A1 (it) | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina | |
| DK3984528T3 (da) | Farmaceutiske sammensætninger, som omfatter nilotinib | |
| DK2073795T3 (da) | Misbrugssikret lægemiddelformulation | |
| DK2277509T3 (da) | DPP IV inhibitorformuleringer | |
| EP2128940A4 (en) | QUANTUM CASCADE LASER | |
| EP2101745A4 (en) | ADMINISTRATION OF MEDICINES | |
| BRPI0719393A2 (pt) | Composição farmacêutica | |
| EP2191826A4 (en) | PHARMACEUTICAL COMPOSITION | |
| DK3492069T3 (da) | Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid | |
| DK2034951T3 (da) | Rehydererbart farmaceutisk produkt | |
| RU2398586C3 (ru) | Фармацевтическая композиция | |
| DK2966175T3 (da) | Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat | |
| UY30410A1 (es) | Aminopirazolopiridinas sustituidas y sus sales, composiciones farmaceuticas que las comprenden, metodos para prepararlas y sus usos | |
| DK2120884T3 (da) | Farmaceutisk sammensætning | |
| BRPI0807078A2 (pt) | Composto, e, formulação farmacêutica | |
| EP2099789A4 (en) | INHIBITORS OF HIV REPLICATION | |
| PT2209464E (pt) | Composição farmacêutica antimalárica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal (granting procedure) |